The ALOFT-IPF Trial Met Its Endpoint. Real Access Is Years Away.

Bristol Myers Squibb's Phase 3 ALOFT-IPF trial met its primary endpoint October 12. The drug, admilparant, slowed lung function decline in about 1,255 adults with idiopathic pulmonary fibrosis (Investing.com, 2026, https://www.investing.com/news/company-news/bristol-myers-squibbs-admilparant-meets-phase-3-ipf-trial-goal-93CH-4943959). The 60 mg dose hit statistical significance at 52 weeks; the 120 mg dose slowed decline numerically but didn't reach significance.

I have pulmonary fibrosis. Different flavor—mine's silica-induced, not idiopathic.

Here's the gap nobody talks about: October 12, 2026 is when Bristol Myers Squibb announced the result. If they file for FDA approval in early 2027, and FDA grants standard review, that's 12 to 18 months. Call it mid-2028 for approval. Then payers write coverage policies, prior authorizations get built, pulmonologists update their treatment algorithms. For a rare condition, real-world access lags approval by another year, maybe two.

So 2029, 2030—somewhere in there—is when the first non-trial patient might actually get prescribed admilparant. Four years from the announcement. Longer from when the trial started enrolling.

Admilparant targets idiopathic pulmonary fibrosis specifically; silica-induced PF is a different mechanism. The benefit is for the IPF cohort—those diagnosed in 2028, 2029, when admilparant is already approved and the prior-auth workflows are running and enough pulmonologists have prescribed it that the institutional knowledge exists.

I track these trials as evidence the problem isn't untouchable. Nintedanib and pirfenidone already proved fibrosis can be slowed. Admilparant working through a different pathway—LPAR1 inhibition instead of tyrosine kinase or antioxidant mechanisms—means more IPF patients might respond, or tolerate treatment when the first two don't work.

That's the practical read: a third option, for the people who need it, years from now.

There's also the liver question. Antifibrotics have a hepatotoxicity history. Both existing drugs require liver monitoring. One source reported that Bristol Myers Squibb added liver injury as an important potential risk to the long-term extension plan, but the ALOFT-IPF liver data hasn't been released. A drug that slows lung fibrosis but crashes your liver isn't an improvement.

The mechanistic detail that caught my attention: the higher dose failed where the lower dose worked. That's not intuitive, but it's not rare. Receptors saturate, off-target effects dominate, therapeutic windows turn out narrower than the dose-escalation model predicted. Biology isn't linear. More drug doesn't always mean more effect.

For newly diagnosed IPF patients in 2029, admilparant might be first-line. For people already on nintedanib or pirfenidone who hit intolerance, it's an alternative. For people who don't respond to the existing options, it's a different mechanism to try.

The diagnosis is terminal. Research that works means the next patient's options are better.

But the trial met its endpoint. Over a thousand participants, statistically significant FVC improvement at 52 weeks, discontinuation rates comparable to placebo. That's real.

The people diagnosed with IPF next year, and the year after, get a longer runway. Maybe long enough that the fourth mechanism, or the fifth, catches them before the disease does.

That cohort is IPF patients. The trial worked.

Sources:
Bristol Myers Squibb announcement: https://www.nasdaq.com/press-release/bristol-myers-squibb-announces-phase-3-aloft-ipf-trial-evaluating-admilparant-adults
ALOFT-IPF trial details: https://clinicaltrials.gov/study/NCT04308681